Integrative Care for OUD and Health Strategies for Chronic Pain

Explore integrative care for OUD and chronic pain and discover effective treatment strategies for better health outcomes.

Abstract

Welcome to this in-depth exploration of modern, evidence-based approaches to managing opioid use disorder (OUD) and chronic pain. I am Dr. Alex Jimenez, and I am honored to guide you through the latest findings from leading researchers in the field. This comprehensive educational post will delve into the complexities of using medications like buprenorphine, methadone, and naltrexone. We will examine the physiological underpinnings of these treatments, compare different buprenorphine initiation protocols—including traditional, low-dose (microdosing), and high-dose methods—and discuss their respective risks and benefits, especially in the context of the potent synthetic opioid, fentanyl. We will explore the advantages of long-acting injectable (LAI) buprenorphine, its various formulations, such as the transdermal patch (Butrans) and buccal film (Belbuca), its use in special populations such as pregnant and adolescent patients, and its role in perioperative care.

Furthermore, I will detail the use of methadone, highlighting its long-standing efficacy, regulatory landscape, and critical safety considerations like QTc interval monitoring. Finally, we will touch upon naltrexone as an alternative treatment and discuss the unique analgesic properties of buprenorphine for chronic pain management. Throughout this discussion, I will integrate insights from my clinical practice at Injury Medical Clinic PA, explaining how our multidisciplinary team, under the medical direction of Dr. Maria Guadalupe Cardenas, MD, combines chiropractic care, functional medicine, and conventional medical oversight to provide comprehensive, patient-centered care. Our goal is to empower you with the knowledge to understand these advanced therapeutic strategies and how they can be tailored to meet individual patient needs for a successful journey toward recovery and wellness.

My Integrative Mission: Who We Are and How We Help

Hello, and thank you for joining me. I am Dr. Alex Jimenez. My extensive background, which includes credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), Certified Functional Medicine Practitioner (CFMP, IFMCP), and certifications in Advanced Toxinology (ATN) and Cranial Cervical Spinal Tomography (CCST), provides me with a unique, panoramic view of patient health. My clinical work bridges chiropractic care, family nurse practitioner training, and functional medicine. Our clinical home is Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. We have cultivated a truly integrative and multidisciplinary environment to treat patients with musculoskeletal injuries, chronic pain, and complex conditions including opioid use disorder. Our model is deliberately multidisciplinary because patient needs are complex—and comprehensive care requires a team.

I am privileged to work alongside Dr. Maria Guadalupe Cardenas, MD, our esteemed Medical Director and Collaborative Physician. Dr. Cardenas is Board Certified in Internal Medicine and brings over 40 years of invaluable experience as an internist to our practice. Her NPI number is 1164426749, and she holds Texas MD License #J2933. This collaborative structure, where an MD provides medical direction alongside a chiropractor, is foundational to our approach, particularly in complex cases involving personal injury, chronic pain, and, as we will discuss today, the management of opioid use disorder (OUD).

• Maria Guadalupe Cardenas, MD, provides medical oversight, medication management, and an internal medicine perspective to our protocols for OUD, pain, and comorbid conditions.
• I provide integrative chiropractic care, biomechanical assessment, functional medicine evaluation, rehabilitation planning, and coordination with medical and behavioral specialists.
• Together, we align medications for opioid use disorder, functional rehabilitation, chiropractic adjustments and manual therapies, movement and stabilization programming, and behavioral health referrals to meet patients where they are and help them move safely toward recovery.

This partnership is a cornerstone of how we manage complex conditions. While my primary focus is chiropractic adjustments, biomechanics, functional medicine, and rehabilitation, Dr. Cardenas provides the crucial medical oversight needed for a truly holistic approach. As a Collaborative Physician, she is deeply involved in case reviews, treatment planning, and, importantly, managing pharmacological therapies. This is how we reduce risks of relapse, prevent falls into unmanaged pain, and make treatments like buprenorphine truly sustainable.

You can learn more about my practice and clinical thinking at:

• Clinical observations and practice insights: https://personalinjurydoctorgroup.com/
• Professional background and updates: https://www.linkedin.com/in/dralexjimenez/

Why Medications for Opioid Use Disorder Are Central to Saving Lives

When a patient presents with opioid use disorder, the most urgent medical task is stabilization: stopping withdrawal, reducing cravings, and sharply lowering mortality risk. Medications for OUD—particularly buprenorphine and methadone—do this reliably.

• Lifesaving effect: Treatment with buprenorphine or methadone reduces opioid-related mortality compared with no treatment by addressing the neurobiological drivers of compulsive use and preventing toxic exposures (Sordo et al., 2017).
• Symptom relief: These medications reduce acute withdrawal and cravings, enabling patients to reconnect with work, school, family, and life goals.
• Harm reduction: Access to medications should not depend on a patient’s readiness to engage in behavioral programs. We prioritize safety and stabilization first, then invite behavioral and rehabilitative supports as patients are ready.

Behavioral health remains a cornerstone of long-term recovery; however, it is ethically and clinically essential that medication access not be contingent on program participation when a patient presents for care.

Opioid Pharmacology: Understanding Mu-Opioid Receptor Activity and Why It Matters

To choose the right therapy and set expectations, we teach patients and families how opioids interact with the mu-opioid receptor:

• Mu-opioid receptor functions: The mu-opioid receptor is central to analgesia, euphoria, and respiratory suppression. It regulates nociception, reward, stress response, and respiration. Engaging this receptor modulates pain signaling and affects dopamine and GABA pathways that shape reward and reinforcement.
• Full agonists (e.g., heroin, oxycodone, fentanyl, methadone): These substances occupy and activate mu receptors to a high degree. This is like a key that fits perfectly into a lock and turns it all the way. It produces the maximum possible opioid effect, including pain relief but also significant euphoria, sedation, and a high risk of respiratory depression, especially with other depressants or comorbid pulmonary disease.
• Partial agonists (buprenorphine): Buprenorphine is a partial agonist with very high binding affinity for mu receptors. It binds strongly, displacing full agonists, but activates the receptor to a lesser extent. This is like a key that fits the same lock but can only turn it partway. This creates a “ceiling effect” on receptor activation. Once the plateau is reached, increasing the dose does not significantly increase the risk of respiratory depression. This explains buprenorphine’s superior safety profile in most settings and its clinical utility for OUD and certain chronic pain contexts (Strain et al., 2020).
• Antagonists (naltrexone): These occupy mu receptors without activating them—blocking the effects of opioids. They are effective for preventing a return to opioid effects when patients are fully detoxified. Still, they are not for pain relief and are not suitable in the presence of physiological opioid dependence without precipitating severe withdrawal.

This pharmacodynamic framework helps us counsel patients on benefits and risks, match therapy to goals (e.g., OUD stabilization vs. chronic pain modulation), and prevent complications.

Navigating Buprenorphine Initiation: A Patient-Centered Approach

As a clinician working at the intersection of pain, functional medicine, and addiction science, I have watched opioid use disorder evolve under the pressures of illicitly manufactured fentanyl. With each patient, the question is not simply how to start buprenorphine, but how to design a safe, humane, and effective plan that accounts for physiology, psychology, and context. When we consider initiating a patient on buprenorphine, it’s crucial to recognize that there is no one-size-fits-all protocol. The most critical step is a collaborative conversation with the patient. We must tailor the approach to their unique circumstances.

What Is Precipitated Withdrawal And Why It Feels So Severe

Because of its high affinity, when buprenorphine is introduced too soon after full agonist use, it can displace the full agonist and trigger a sudden drop in receptor activation—this is precipitated withdrawal. It is the rapid onset of objective withdrawal signs after administering buprenorphine in an opioid-dependent person who still has full agonists occupying receptors. Clinically, I see patients describe it as the worst withdrawal they have ever experienced. Symptoms include pupillary dilation, piloerection (gooseflesh), extreme restlessness, vomiting, diarrhea, runny nose, and a terrifying surge of anxiety. The Clinical Opioid Withdrawal Scale (COWS) typically rises by at least five points in the first minutes to hours.

In my practice, I always explain the receptor story to patients:

• When receptors are unoccupied, withdrawal is felt.
• When full agonists occupy receptors, withdrawal decreases.
• When a full dose of buprenorphine is introduced while full agonists still bind receptors, buprenorphine displaces them, and patients can experience rapid, severe withdrawal.

Fentanyl-Specific Challenges: Lipophilicity, Receptor Dynamics, And Clinical Presentation

Fentanyl changes the game.

• Fentanyl is highly lipophilic, meaning it stores in adipose tissue and can leak back into circulation over time after apparent cessation. This makes timing tricky.
• Withdrawal can begin soon after last use, but precipitated withdrawal can occur farther out than with heroin or short-acting opioids because fentanyl continues to redistribute.
• Fentanyl users often present with severe restlessness and anxiety, sometimes overshadowing GI and other classic signs. Clinicians should not misattribute these symptoms to purely psychiatric causes; they are part of fentanyl-associated withdrawal.
• Many patients have attempted buprenorphine before, and fear precipitated withdrawal. Their experiences and preferences must guide the method we choose.

Shared Decision-Making: Empowering Patients with Choice

I prioritize conversations that respect autonomy. Research and guidelines highlight the value of individualization based on patient preferences. In practice, this means explaining all available approaches clearly and discussing the time since last opioid use, severity of withdrawal, and patient priorities. I share quotes from qualitative studies because patients have taught us how to do this well:

• “My doctor told me, ‘ Do what I feel comfortable doing. That was so nice.” This reflects autonomy and collaboration.
• “Withdrawal is not just flu-like. The anxiety and hopelessness can be crushing.” We must validate the mental and emotional weight of withdrawal, especially with fentanyl.

COWS As A Tool—And Its Limits

The Clinical Opioid Withdrawal Scale (COWS) is an 11-item scale capturing objective and subjective signs of opioid withdrawal. With fentanyl, anxiety and restlessness may precede other markers, so I pair COWS with careful patient narrative. A patient’s COWS score (often a target of 8–12 for traditional induction) helps guide timing, but treatment decisions should not be made solely on COWS, as redistribution can surprise us.

Crucial Safety Questions Before Starting Buprenorphine

Before prescribing buprenorphine, a thorough risk assessment is non-negotiable. Here are the questions I always address:

• Concurrent Use of Other Substances: I ask explicitly about the use of benzodiazepines, alcohol, or other sedating substances. The combination of buprenorphine with these central nervous system depressants significantly increases the risk of respiratory depression, which can be fatal. This is one of the most important warnings I give to patients.
• Comorbid Medical Conditions: I need to know about the patient’s overall health. Do they have a history of heart disease, neurocognitive impairments, or liver disease? Buprenorphine is metabolized by the liver (CYP3A4), so in patients with elevated liver enzymes or known liver impairment, we monitor LFTs. Severe impairment may require dose adjustments.
• History of Precipitated Withdrawal: If a patient has experienced this before, they will be terrified of it happening again. I take the time to educate them about what precipitated withdrawal is, why it happens, and the specific risks of each initiation method.
• Safe Environment for the Transition: I ask, “Do you have a safe place to stay for the next few days? Do you have access to a private bathroom?” The withdrawal process can be intense. A simple but effective comfort measure is a hot shower or bath. Many of my patients have found that this helps tremendously with the muscle cramps and deep, aching soreness that often accompany opioid withdrawal.

Three Approaches To Buprenorphine Initiation: Traditional, Low-Dose, and High-Dose

The American Society of Addiction Medicine (ASAM) emphasizes individualizing initiation based on patient preference (ASAM, 2020). Patients using high-potency synthetic opioids may require >16 mg/day for stabilization, sometimes >24 mg/day. We have three main strategies.

1. Traditional Buprenorphine Initiation: When And How I Use It

This method involves starting buprenorphine after a defined period of abstinence once mild to moderate withdrawal is present (e.g., COWS> 8–12).

• Appropriate for: Patients switching from short-acting full agonists (e.g., heroin, oxycodone) and some who are not using fentanyl.
• Abstinence windows:

• • Short-acting opioids: 12–24 hours
  • Long-acting opioids/methadone: 24- 72+ hours
  • Fentanyl: At least 48 hours is safer due to lipophilic storage.

• Dosing: Start with 2–4 mg sublingual; titrate in 2–4 mg increments to relieve withdrawal/cravings, typically reaching 8–16 mg/day on day 1–2.
• Advantages: Familiar and straightforward.
• Disadvantages: Higher risk of precipitated withdrawal in fentanyl users. It can be difficult for patients to maintain abstinence long enough.

2. Low-Dose Buprenorphine Initiation (Microdosing or Bernese Method)

This involves the gradual up-titration of buprenorphine while patients continue full agonists until buprenorphine occupancy is sufficient to stop them with minimal or no withdrawal.

• Concept: Gradually introduce very low doses (e.g., 0.25- 0.5 mg) of buprenorphine, allowing it to accumulate on mu receptors over several days. The goal is to avoid withdrawal entirely.
• Ambulatory Example (4-Day):

• • Days 1–3: Patient continues full agonists while buprenorphine is titrated up.
  • End of Day 3: Typically around 8 mg/day, offering some overdose protection.
  • Day 4: Full agonists are stopped, and buprenorphine dosing increases.

• Advantages: Patient-preferred for those fearful of withdrawal and has a lower risk of precipitated withdrawal.
• Disadvantages: Requires cutting films/tablets, and patients must continue full agonists during titration, necessitating overdose prevention counseling. It requires high care coordination and frequent check-ins.

3. High-Dose Buprenorphine Initiation: Rapid and Structured

This method is increasingly used, especially in urgent care settings.

• Method:

• • Confirm time since last use (at least 12 hours for fentanyl).
  • Obtain COWS >16 and at least two objective signs (e.g., dilated pupils, piloerection).
  • Give 8–16 mg buprenorphine; for fentanyl, 16 mg is common.
  • Observe for 30 minutes; if tolerated, add 8 mg as needed, up to 32 mg on day one.
  • Day two: continue 24–32 mg/day, especially with fentanyl

• Advantages: Rapid transition and simple dosing.
• Disadvantages: If precipitated withdrawal occurs, it can be severe. Careful patient selection and observation are essential.

Adjunct Medications: Symptom-Targeted Support

During any initiation, I use symptom-targeted pharmacology to improve comfort and safety:

• Clonidine for restlessness and anxiety
• Tizanidine for muscle cramps/generalized pain
• Hydroxyzine for anxiety, restlessness, sleep
• Trazodone for sleep
• Ondansetron for nausea/vomiting
• NSAIDs or Acetaminophen for pain
• Loperamide for diarrhea

Buprenorphine Formulations: A Spectrum of Choices

Buprenorphine comes in multiple formulations, each with specific indications.

• For OUD:

• • Sublingual buprenorphine monoproduct (historically “Subutex” ): Sometimes favored if patients have an intolerance to naloxone.
  • Sublingual buprenorphine/naloxone (e.g., Suboxone): The standard for office-based OUD treatment. Naloxone primarily deters injection.
  • Long-acting injectables (LAIs): Sublocade (monthly) and Brixadi (weekly or monthly).

• For Chronic Pain:

• • Butrans (transdermal patch)
  • Belbuca (buccal film)
  • Buprenex (injectable, for acute pain)

Sublingual products for OUD are sometimes prescribed off-label for chronic pain, especially in complex cases where OUD and chronic pain coexist. This requires careful oversight by our medical team.

The Rise of Long-Acting Injectable Buprenorphine

For many patients, long-acting injectable (LAI) buprenorphine is becoming the standard of care for the continuation phase of treatment.

Understanding Sublocade (Monthly Injection)

• Dosing: Patients typically start with two 300 mg doses one month apart, then transition to a 100 mg or 300 mg monthly maintenance dose.
• Steady State: It takes four to six months to reach a stable concentration. Patients need to understand this.
• Prerequisite: Patients must first tolerate at least 8 mg of sublingual buprenorphine for a minimum of seven days.
• Supplemental Dosing: Many patients need supplemental sublingual buprenorphine during the first few months.

Understanding Brixadi (Weekly or Monthly Injections)

• Dosing Flexibility: Offers both weekly and monthly dosing options.
• Direct Initiation: Evolving evidence supports direct initiation onto the weekly injection while a patient is in moderate withdrawal, bypassing the sublingual stabilization phase.
• End-of-Month Considerations: Serum levels can sometimes fall at the end of the monthly interval, potentially requiring supplemental dosing.

Advantages of LAIs:

• Improved Adherence and Treatment Retention: Removes the daily burden of taking medication.
• More Consistent Plasma Concentrations: Eliminates the daily peaks and troughs of sublingual forms, which may better control cravings.
• Diversion Prevention: Medication is administered in-clinic.

Disadvantages of LAIs:

• Injection Site Reactions: Pain, redness, or itching can occur.
• Cost and Insurance Coverage: These medications are expensive and can be an administrative burden for clinics.
• Complicated Billing: Often requires a “buy-and-bill” model, which is a financial barrier for smaller practices.

How to Take Sublingual Buprenorphine Correctly

We teach patients to optimize absorption and reduce side effects:

• Place the tablet or film under the tongue. Do not chew or swallow.
• Allow it to dissolve fully—up to 10 minutes. Do not eat, drink, or smoke during this time.
• If nausea occurs, spit out excess saliva during dissolution.
• Use meticulous dental hygiene: Rinse with water after the medication dissolves. Wait until the mouth is clear, then brush gently. See a dentist regularly. Case reports have linked sublingual buprenorphine to dental caries, but good hygiene significantly mitigates this risk.

Planning for Long-Term Success: Dosing and Follow-Up

A critical point to understand, especially with illicitly manufactured fentanyl, is that standard dosing may not be sufficient. Fentanyl’s high potency and lipophilic nature mean patients often require higher doses of buprenorphine.

• Higher Dosing for Fentanyl Use: Many patients will need more than the previously standard 24 mg per day. The FDA recently adjusted its approval for buprenorphine dosing, allowing for increases up to 32 mg per day in certain cases.
• Navigating Insurance Barriers: Most insurance companies now cover doses up to 32 mg, but our staff often needs to advocate for patients by completing prior authorizations.
• Continuity of Care: A seamless link to community providers is crucial. If you are a hospitalist or ED physician, invest time in building referral pathways. Our clinic strives to be a reliable community resource.

Methadone: The Gold Standard with Strict Regulations

Methadone, a full mu agonist, remains a powerful tool for OUD. It has been used since the 1970s and has decades of robust evidence supporting its efficacy.

• Pharmacokinetics: Methadone has a very long and variable half-life (8 to 65 hours), and it can take four to seven days to reach a steady state. This requires very careful and slow dose titration to avoid “dose stacking,” which can lead to over-sedation and respiratory depression.
• Indications: Indicated for OUD within regulated opioid treatment programs (OTPs), especially for patients who do not respond to buprenorphine. It is also effective for analgesia, making it a consideration for severe chronic pain coexisting with OUD.
• Regulatory Landscape: For OUD treatment, methadone can only be dispensed from a licensed OTP. Physicians in general practice cannot prescribe it for OUD, though they can for pain. However, it is legal to initiate and adjust methadone for OUD during a patient’s hospitalization. Hospitals can also dispense a three-day supply at discharge to bridge a patient to an OTP.
• Safety Considerations:

• • QTc Prolongation: Methadone is known to prolong the QTc interval on an ECG, increasing the risk of a life-threatening arrhythmia. Check baseline QTc before starting.
  • Drug-Drug Interactions: It has many potential interactions via the cytochrome P450 system. A full medication reconciliation is essential.

Naltrexone: An Antagonist Option

Naltrexone is an opioid antagonist that works by blocking the mu-opioid receptor.

• Role in Treatment: It is best for highly motivated patients who are fully detoxified and desire a non-opioid maintenance strategy. Unlike buprenorphine and methadone, it does not treat withdrawal symptoms or cravings.
• Initiation Requirements: A patient must be completely opioid-free for 7 to 10 days before starting, which is a major barrier.
• Formulations: Available as an oral tablet (50 mg daily) and a long-acting intramuscular injection (Vivitrol, 380 mg once every four weeks).
• Counseling: Patients need to know that any opioids they might need for legitimate medical reasons (e.g., surgery) will be less effective.

Integrating Chiropractic and Functional Medicine With OUD and Chronic Pain Care

Medication stabilizes physiology; integrative care restores lives. This is where my dual training in chiropractic and functional medicine supports recovery.

• Chiropractic Assessment and Adjustments:

• • Identify segmental dysfunctions and movement restrictions that amplify pain signals.
  • Adjustments can modulate pain via gate control mechanisms and descending inhibitory pathways, reducing the risk of central sensitization.
  • Restoring joint mechanics reduces aberrant movement patterns that perpetuate pain.

• Functional Rehabilitation:

• • Progressive motor control and strength programming recalibrate movement patterns.
  • Gradual exposure decreases fear-avoidance behaviors and improves confidence.

• Functional Medicine:

• • Address inflammatory drivers (nutrition, micronutrient deficiencies, gut permeability, sleep dysregulation).
  • Optimize metabolic health to support healing.
  • Implement stress regulation techniques (e.g., breathwork) to decrease allostatic load.

• Personal Injury Care Synergy:

• • For patients injured in accidents, we align acute injury care with OUD stabilization to prevent relapse and reduce pain catastrophizing.

These interventions can reduce the required pharmacologic load, enhance quality of life, and protect recovery trajectories. Drawing from my ongoing clinical observations (see personalinjurydoctorgroup.com and linkedin.com/in/dralexjimenez), patients stabilized on buprenorphine who engage in structured movement plans report faster improvements in sleep and mood.

The Science of Pain in OUD: Peripheral and Central Mechanisms

Understanding why some patients have persistent pain despite stable medication helps us choose effective adjuncts.

• Peripheral Nociception: Tissue injury releases inflammatory mediators that sensitize local nerves.
• Central Sensitization: Persistent pain input increases NMDA receptor activity and microglial activation in the central nervous system. The nervous system becomes “loud,” amplifying non-painful input into pain perception.
• Opioid-Induced Hyperalgesia (OIH): Long-term exposure to full agonists may paradoxically increase pain sensitivity. Buprenorphine’s unique properties, including kappa antagonism, may mitigate OIH in some patients (Lee et al., 2011).
• Biopsychosocial Factors: Stress, sleep deprivation, and trauma exacerbate pain processing.

Our model addresses each layer: stabilize opioid systems, reduce peripheral drivers via manual therapy, retrain central processing through graded exposure, and modulate systemic inflammation and stress.

Buprenorphine for Chronic Pain: A Unique Tool

For the right patient, buprenorphine can be an incredibly useful tool for managing chronic pain, offering a better safety profile than traditional full agonist opioids. Its unique pharmacology—partial mu-agonism and kappa-antagonism—provides stable pain relief with less euphoria, a ceiling on respiratory depression, and a reduced risk of opioid-induced hyperalgesia.

• Identifying Candidates: We first rule out active OUD and exhaust non-opioid options. Buprenorphine is ideal for patients with inadequate relief from other therapies or those at high risk from full-agonist opioids (e.g., older adults, patients with sleep apnea).
• Formulations for Pain:

• • Transdermal Patch (Butrans): Delivers a slow, continuous dose over seven days. Best for opioid-naïve patients or those on < 80 MME/day. The max dose is 20 mcg/hour. Patients must rotate application sites and avoid direct heat.
  • Buccal Film (Belbuca): A small film placed on the inside of the cheek, dosed every 12 hours. It offers more flexibility and higher doses (up to 900 mcg every 12 hours) for patients with greater analgesic needs.

• Off-Label Use: For patients on very high doses of full agonists (> 160 MME/day) or those who have failed other buprenorphine formulations, we may consider off-label sublingual buprenorphine for pain. This requires deep expertise and is a perfect example of where our collaborative care model ensures safety.

Special Populations and Comorbidities

Our approach is tailored for various patient groups:

• Pregnant Patients: Treatment with buprenorphine is the recommended standard of care. Either sublingual formulation is considered safe. Doses often need to be higher and/or split due to physiologic changes in pregnancy. Injectable forms are not yet FDA-approved for use in pregnancy.
• Perioperative Patients (Undergoing Surgery): The answer is almost always to continue buprenorphine throughout the entire perioperative period. Stopping it would cause withdrawal and increase relapse risk. Postoperative pain management must be multimodal, often requiring non-opioid strategies and higher-than-usual doses of short-acting full agonists if needed.
• Adolescents: Buprenorphine is FDA-approved for OUD in adolescents aged 16 and older. The primary goal is often overdose protection, which requires a dose of at least 8 mg to achieve a significant “blockade” effect.
• Liver Disease: We monitor LFTs and adjust dosing as needed. Buprenorphine is generally safer than full agonists.
• Benzodiazepines and Alcohol: We do not withhold buprenorphine for OUD if a patient is taking benzodiazepines. Instead, under Dr. Cardenas’s guidance, we coordinate a risk-reduction plan, which may include a gradual taper. We counsel on the synergistic sedation risk with alcohol.

Harm Reduction: Meeting People Where They Are

We align with modern harm-reduction principles. This is a pragmatic approach aimed at reducing the negative consequences of drug use.

• Naloxone is Non-Negotiable: Always prescribe naloxone. I tell every patient on buprenorphine: “You are right that your personal risk is much lower now. However, you might be in a position to save the life of a friend, a family member, or even a stranger.” It empowers patients to become part of the solution.
• Assume EVERYTHING Contains Fentanyl: I tell patients, “You must assume that anything bought off the street is likely to contain fentanyl. There is no quality control.”
• Low-Threshold Access: We provide low-threshold access to buprenorphine and do not require behavioral program participation to start lifesaving medication.
• Safe Practices: For patients who are not ready to stop using, we have non-judgmental conversations about safer use practices, such as never sharing injection equipment and understanding that smoking fentanyl carries a lower risk of fatal overdose than injecting it.

Closing Perspective: Safety, Dignity, and Function

Medications for OUD save lives; integrative care restores lives. By weaving the pharmacologic foundation of buprenorphine, methadone, and naltrexone with chiropractic, functional medicine, rehabilitation, and harm-reduction practices, we meet patients where they are and walk with them toward health. This comprehensive, team-based approach, with Dr. Cardenas providing essential medical direction and our entire team contributing their expertise, allows us to treat the whole person, not just their addiction or their pain.

If you, your patient, or a family member needs help, know that compassionate, evidence-based, integrated care is available. Our team in El Paso stands ready to assist.

Learn more:

• https://personalinjurydoctorgroup.com/
• https://www.linkedin.com/in/dralexjimenez/

References

Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: Five-year experience. Archives of Internal Medicine, 171(5), 425–431.

American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine, 14(2S), 1–91.

American Society of Addiction Medicine. (2023). Clinical considerations for buprenorphine initiation and stabilization.

[Belbuca (buprenorphine) buccal film [Prescribing Information]. (2023). BioDelivery Sciences International, Inc.](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207932s015lbl.pdf)

California Bridge. Buprenorphine in the ED/urgent care: High-dose initiation protocols.

Chen, Y., Yang, C., & Wang, Z. J. (2018). Buprenorphine: A promising new treatment for opioid-induced hyperalgesia. The Journal of Pain, 19(3), 235-245.

Dahan, A., Yassen, A., Bijl, H., Romberg, R., Sarton, E., Teppema, L., Van Oene, J., & Danhof, M. (2006). Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. British Journal of Anesthesia, 96(5), 627–632.

Dahan, A., van der Schrier, R., Smith, T., & Aarts, L. (2020). Buprenorphine, a treatment for opioid dependence and pain. Anesthesiology, 133(5), 1109–1121.

Dowell, D., Ragan, K. R., Jones, C. M., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR. Recommendations and Reports, 71(No. RR-3), 1–95.

Fudin, J., Schatman, M. E., & Cleary, J. P. (2016). The risk of respiratory depression with buprenorphine: What is the evidence? Journal of Pain Research, 9, 459–475.

Hser, Y. I., Mooney, L. J., Saxon, A. J., Miotto, K., Bell, D. S., Zhu, Y., Liang, D., & Huang, D. (2017). High mortality among patients with opioid use disorder in a large healthcare system. Journal of Addiction Medicine, 11(4), 315–319.

Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, D. A., Oga, E. A., Bigelow, G. E., & Silverman, K. (2018). Extended-release injectable naltrexone for opioid use disorder: A systematic review. Addiction, 113(7), 1188–1209.

Jimenez, A. Clinical observations in integrative injury care. Personal Injury Doctor Group.

Jimenez, A. Professional profile and clinical insights. LinkedIn.

Kampman, K., & Jarvis, M. (2015). American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine, 9(5), 358–367.

Klevecka, A., Frost, M., & Soyka, M. (2019). Buprenorphine in the treatment of opioid dependence: A review. European Addiction Research, 25(4), 157–169.

Kornfeld, H., & Manfredi, L. (2010). Effectiveness of buprenorphine maintenance for heroin dependence: A clinical study. Journal of Addictive Diseases, 29(1), 89–98.

Korthuis, P. T., McCarty, D., Weimer, M., Bougatsos, C., Blazina, I., Zakher, B., Grusing, S., & Chou, R. (2017). Primary care–based models for the treatment of opioid use disorder: A scoping review. Annals of Internal Medicine, 166(4), 268–278.

Krashin, D., Sullivan, M., & Ballantyne, J. (2013). Opioid therapy for chronic noncancer pain: Progress and continued challenges. Journal of Pain, 14(1), 1–19.

Kreek, M. J., Reed, B., & Butelman, E. R. (2019). Current status of opioid addiction treatment and related preclinical research. Science Advances, 5(10), eaax9140.

Lalanne, L., Ayranci, G., Kieffer, B. L., & Lutz, P. E. (2014). The kappa opioid receptor: from addiction to depression, and back. Frontiers in Psychiatry, 5, 170.

Lee, M., Silverman, S. M., Hansen, H., Patel, V. B., & Manchikanti, L. (2011). A comprehensive review of opioid-induced hyperalgesia. Pain Physician, 14(2), 145–161.

Lintzeris, N., Dunlop, A., & Haber, P. (2020). Managing opioid dependence with buprenorphine: Clinical guidelines. Drug and Alcohol Review, 39(1), 73–84.

Martin, S. A., Chiodo, L. M., & Bosse, J. D. (2018). The Next Stage of Buprenorphine Care for Opioid Use Disorder. Annals of Internal Medicine, 169(9), 628.

Oregon Health & Science University. Shared decision-making in buprenorphine initiation: Qualitative insights.

Pain and Therapy. (2021). Buprenorphine for Chronic Pain: A Review of the Clinical Evidence. Pain and Therapy, 10(1), 195–213.

Pergolizzi, J. V., Raffa, R. B., & LeQuang, J. A. (2019). The role of buprenorphine in the management of chronic pain. Pain Management, 9(5), 455- 467.

Schofferman, J. (2018). The use of buprenorphine for chronic pain. Pain Medicine, 19(Suppl_1), S5–S10.

Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. Addiction, 112(12), 2133-2145.

Soyka, M. (2015). Treatment of opioid dependence with buprenorphine: Current update. Dialogues in Clinical Neuroscience, 17(3), 321–335.

Srivastava, A., Kahan, M., & Nader, M. (2022). The Bernese method for buprenorphine/naloxone induction in people who use fentanyl: a case series. The American Journal of Drug and Alcohol Abuse, 48(3), 324–331.

Strain, E. C., & Stoller, K. B. (2020). The treatment of opioid use disorder. In A. Tasman, J. Kay, & J. A. Lieberman (Eds.), Psychiatry (pp. 1–15). Wiley.

Substance Abuse and Mental Health Services Administration. (2021). Federal guidelines for opioid treatment programs. SAMHSA.

U.S. Food and Drug Administration. (2023). FDA approves higher dose of buprenorphine for opioid use disorder. FDA News Release.

U.S. Food and Drug Administration (FDA). (2017). Butrans (buprenorphine) Transdermal System: Drug Safety Communication – Risk of Serious Burns from Overheating of Patch.

Volkow, N. D., & McLellan, T. (2016). Opioid abuse in chronic pain—Misconceptions and mitigation strategies. New England Journal of Medicine, 374(13), 1253–1263.

Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55(5), 569–580.

Webster, L. R. (2017). Buprenorphine for chronic pain: A safer alternative to full agonist opioids? Pain Medicine, 18(suppl_1), S3-S4.

Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259.

SEO Tags: opioid use disorder, buprenorphine, buprenorphine initiation, methadone, naltrexone, precipitated withdrawal, fentanyl lipophilicity, low-dose microdosing buprenorphine, high-dose buprenorphine ED, ASAM buprenorphine guidelines, COWS scale opioid withdrawal, integrative chiropractic care, functional medicine, harm reduction, chronic pain management, El Paso injury clinic, personal injury rehabilitation, long-acting buprenorphine, Sublocade, Brixadi, Butrans, Belbuca, pain management clinic, opioid safety, MME calculation, naloxone, Suboxone for pain, off-label buprenorphine, dental health buprenorphine, liver function monitoring, benzodiazepine co-use, Medical Director Dr. Maria Cardenas, Dr. Alex Jimenez